MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,442K
Net Income
-$30,995K
Net Profit Margin
-2149.45%
EPS
-$0.08
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenues
1,442
14,228
581
18,306
Research and development
26,570
31,438
28,142
27,084
Impairment of long-lived assets
-
13,235
0
0
General and administrative
6,818
7,758
7,992
9,077
Total operating expenses
33,388
52,431
36,134
36,161
Loss from operations
-31,946
-38,203
-35,553
-17,855
Interest income
300
252
355
386
Other income (expense), net
651
-21
107
-2,490
Loss before income taxes
-30,995
-37,972
-35,091
-19,959
Income tax expense
0
-553
-161
27
Net loss
-
-37,419
-34,930
-19,986
Net income allocated to participating securities
-
-
0
-
Net loss
-30,995
-
-34,930
-
Basic EPS
-0.08
-0.11
-0.11
-0.08
Diluted EPS
-0.08
-0.11
-0.11
-0.08
Basic Average Shares
389,616,000
339,285,000
304,268,000
256,950,000
Diluted Average Shares
389,616,000
339,285,000
304,268,000
256,950,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$30,995K
Loss before income
taxes
-$30,995K
(-1.70%↓ Y/Y)
Other income
(expense), net
$651K
(156.17%↑ Y/Y)
Interest income
$300K
(-2.91%↓ Y/Y)
Loss from operations
-$31,946K
(-7.82%↓ Y/Y)
Revenues
$1,442K
(-77.60%↓ Y/Y)
Total operating
expenses
$33,388K
(-7.42%↓ Y/Y)
Research and development
$26,570K
(2.17%↑ Y/Y)
General and
administrative
$6,818K
(-32.22%↓ Y/Y)
Buy us a coffee
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)